Skip to main content
. 2016 Nov 5;7(51):84594–84607. doi: 10.18632/oncotarget.13141

Figure 6. GSI-I combined with ABT-737 increases the NOXA/MCL-1 protein ratio and inhibit the MIC-mediated tumor formation in vivo.

Figure 6

(A) Protein lysates were prepared under the same treatment conditions as in Figure 5B and probed for PARP, NOXA, MCL-1and TUBULIN. (B) The treatment effects were tested in a xenograft model initiated with a low-number of MIC-enriched cells. For tumor injection, we used the surviving cells from the sphere cultures, upon treatments of GSI-I and ABT-737, either alone or in combination, at the density of 50,000 viable cells per injection. Tumor-free incidence curve shows a significantly longer tumor–free time in the combination group, compared to the vehicle or single drug groups (p < 0.05). (C) Sphere assays with the tumor cells collected at the end of the animal experiment, and the number of spheres was significantly lower in the combination group compared to control or single drug groups (p < 0.001). N = 3. * indicates p < 0.05; *** indicates p < 0.001.